Targeting the gut microbiome in inflammatory bowel disease: from concept to clinical reality
Intestinal Research · 31.10.2025 · 23 (4) · 396-404
DOI: 10.5217/ir.2025.00104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Intestinal Research, erschienen am 31.10.2025. Verfasst von Nathalie Rolhion und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine (CRSA), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: European Research Council, MSDAVENIR.
Abstract (Originalsprache)
The gut microbiota, a complex community of trillions of microorganisms inhabiting the human gastrointestinal tract, has emerged as a critical regulator of immune homeostasis and gastrointestinal health. In the context of inflammatory bowel disease (IBD), comprising primarily Crohn’s disease and ulcerative colitis, disruptions to this microbial ecosystem—collectively termed dysbiosis—have been increasingly recognized as central to disease pathogenesis. Recent research has established that alterations in gut microbiota not only reflect disease states but may actively drive immune dysregulation, barrier dysfunction, and mucosal inflammation. This review synthesizes current knowledge on the role of the gut microbiota in IBD and evaluates the therapeutic landscape of microbiota-modulating strategies using selected examples. Fecal microbiota transplantation, while offering proof-of-concept validation, is hindered by standardization challenges and variable clinical outcomes. As a response, microbiome-based therapeutics have evolved toward defined live biotherapeutic products including bacterial consortia and single-strain products, postbiotics, and metabolite-centered approaches targeting specific pathways. Groundbreaking research into rationally designed synthetic microbiomes and next-generation probiotics is driving a paradigm shift in microbiota-based treatment for IBD from empirical to precision-guided interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine (CRSA), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
- Gut, Liver & Microbiome Research (GLIMMER), FHU, Paris, France.
- Department of Gastroenterology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
- INRAE, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.
Förderung
- European Research Council
- MSDAVENIR
Zitieren
APA
Rolhion, N., & Sokol, H. (2025). Targeting the gut microbiome in inflammatory bowel disease: from concept to clinical reality. Intestinal Research, 23(4), 396-404. https://doi.org/10.5217/ir.2025.00104
Vancouver
Rolhion N, Sokol H. Targeting the gut microbiome in inflammatory bowel disease: from concept to clinical reality. Intestinal Research. 2025;23(4):396-404. doi:10.5217/ir.2025.00104
BibTeX
@article{Rolhion2025,
author = {Rolhion, Nathalie and Sokol, Harry},
title = {Targeting the gut microbiome in inflammatory bowel disease: from concept to clinical reality},
journal = {Intestinal Research},
year = {2025},
volume = {23},
number = {4},
pages = {396--404},
doi = {10.5217/ir.2025.00104}
}
EUVIMED